Pleural Mesothelioma

Pleural Mesothelioma
Type	Malignant neoplasm of the pleura
ICD-10	C45.0
Percentage of Cases	~80% of all mesotheliomas
Annual U.S. Cases	~2,669 (2022 CDC data)
Median Age at Diagnosis	72–78 years
Male-to-Female Ratio	3–4:1
Primary Cause	Asbestos exposure (80–90% of cases)
Latency Period	20–50 years (median 40–45)
5-Year Survival	12% overall (SEER)
FDA-Approved Treatments	Cisplatin+pemetrexed (2004), nivolumab+ipilimumab (2020), pembrolizumab+chemo (2024)
Key Staging System	TNM 8th Edition (AJCC/UICC)

Executive Summary

Pleural mesothelioma is a rare and aggressive cancer that develops in the pleura, the thin membrane lining the lungs and chest cavity. Accounting for approximately 80% of all mesothelioma diagnoses, it is the most common form of this asbestos-related malignancy. The disease is caused almost exclusively by prior exposure to asbestos fibers, with a latency period typically spanning 20 to 50 years between initial exposure and clinical presentation. Despite advances in treatment — including the landmark approval of immunotherapy combinations in 2020 and 2024 — the overall 5-year survival rate remains approximately 12%, underscoring the critical importance of early detection, specialized treatment, and prompt legal action to secure compensation.

At-a-Glance

Pleural mesothelioma at a glance:

• Epithelioid patients survive 3-6x longer than sarcomatoid — median overall survival of 12–27 months versus 4–8 months, making histological subtype the single strongest prognostic factor
• Immunotherapy more than doubled survival in non-epithelioid disease — nivolumab + ipilimumab achieved five-year overall survival of 12% versus 1% for chemotherapy alone in non-epithelioid patients (sarcomatoid and biphasic combined; HR 0.48, 95% CI 0.33–0.68). CheckMate 743 was not randomised on histology, so this is a subgroup finding that no confirmatory trial has yet tested
• Stage I patients survive more than twice as long as Stage IV — 5-year survival of 18–20% compared to 7–8%, underscoring the survival premium of early detection
• Surgery plus chemo performed worse than chemo alone in MARS 2 — extended pleurectomy/decortication yielded 19.3 months median OS versus 24.8 months for chemotherapy only, with 3.6x more serious adverse events — though the trial's interpretation remains contested within the surgical community
• P/D carries half the surgical mortality of EPP — perioperative death rate of approximately 3% at high-volume centers compared to 5–7% for extrapleural pneumonectomy, now the preferred approach when surgery is indicated
• Women survive at nearly 3x the rate of men at 5 years — 13.4% versus 4.5% five-year survival in a SEER analysis of 14,228 cases, despite comprising only 26.8% of diagnoses in the National Cancer Database
• Peritoneal patients survive about three times as long as pleural — peritoneal mesothelioma 5-year survival is approximately 47–49% in CRS/HIPEC surgical series, compared to 15% for pleural mesothelioma across all SEER stages combined (patients diagnosed 2015–2021)
• Veterans face disproportionate risk compared to the general population — military service accounts for a significant share of mesothelioma cases due to decades of asbestos use in naval vessels, barracks, and equipment, with VA disability rated at 100%
• Patients receiving multimodal treatment at specialized centers outlive those on supportive care alone — combination therapy with surgery, chemo, and immunotherapy can extend median survival beyond 2 years versus under 12 months with best supportive care
• Most patients never receive second-line treatment — in an unselected Australian real-world cohort only 40% of patients went on to any second-line therapy after first line, with the remaining 60% moving to best supportive care; where it is given after first-line immunotherapy, pemetrexed plus platinum achieved median overall survival of 17.1 months
• Insulation workers face 46x the expected mesothelioma mortality rate — the highest occupational risk of any trade, compared to single-digit relative risks in lower-exposure occupations

Key Facts

Metric	Finding
Annual U.S. Incidence	2,669 new mesothelioma cases reported in 2022 (CDC U.S. Cancer Statistics); pleural mesothelioma comprises ~80% of all diagnoses; age-adjusted rate declined from 1.08 to 0.65 per 100,000 between 2003 and 2022
CheckMate 743 Overall Survival	Nivolumab + ipilimumab achieved median OS 18.1 months vs. 14.1 months for chemotherapy (HR 0.74); non-epithelioid subgroup 5-year OS 12% vs. 1% (HR 0.48) (Scherpereel, Baas et al., J Clin Oncol, 2026; N=605 randomised, Baas et al., The Lancet, 2021); 5-year OS 14% vs. 6% at extended follow-up (Scherpereel, Baas et al., J Clin Oncol, 2026)
KEYNOTE-483 Overall Survival	Pembrolizumab + pemetrexed + platinum achieved median OS 17.3 months vs. 16.1 months for chemo alone; 3-year OS 25% vs. 17%; ORR 52% vs. 29% (FDA approval September 2024)
MARS 2 Surgery Outcomes	Extended P/D + chemo: median OS 19.3 months vs. 24.8 months chemo alone; surgery group had 3.6x more serious adverse events; Phase 3 RCT across 26 UK hospitals (Lim et al., Lancet Respiratory Medicine, 2024)
EMPHACIS Chemotherapy Landmark	Cisplatin + pemetrexed achieved median OS 12–16 months with response rate 40–45%; FDA approval 2004; remains backbone of first-line chemotherapy (Vogelzang et al., Journal of Clinical Oncology, 2003)
Epithelioid Nuclear Grading	2021 WHO classification introduced formal nuclear grading; high-grade epithelioid tumors carry HR 3.09 for overall survival compared to low-grade, based on mitotic count and nuclear atypia
5-Year Survival by Stage	Stage I: 18–20%; Stage II: ~12%; Stage III: ~14%; Stage IV: 7–8%; overall 5-year relative survival 12% (SEER 2000–2020 data). SEER also reports survival by summary stage rather than TNM, for patients diagnosed 2015–2021: localized 23%, regional 15%, distant 11%, all stages combined 15%
Histological Subtype Distribution	Epithelioid 60–70% (median survival 12–27 months); biphasic 10–20% (8–13 months); sarcomatoid 10–20% (4–8 months); transitional subtype median survival 6.7 months with 0% 5-year survival (WHO 2021 Classification)
CAR-T Phase I Response Rate	Mesothelin-targeted CAR-T cells delivered intrapleurally with pembrolizumab achieved ORR of 72% with 2 complete metabolic responses (Memorial Sloan Kettering Phase I trial); Phase II ongoing
BAP1 Loss as Diagnostic Marker	BAP1 expression loss detected by IHC in approximately 60–70% of epithelioid mesotheliomas; virtually absent in reactive mesothelial proliferations, providing high specificity for malignancy
Serum Biomarker Performance	SMRP/MESOMARK (FDA-approved 2007): pooled sensitivity ~61%, specificity 87%; multi-biomarker panels including fibulin-3 and HMGB1 achieve sensitivities exceeding 90%
Compensation Pathways	60+ asbestos bankruptcy trusts holding $16.0-$21.8 Billion (documented floor, Sept 2026) in remaining funds; combined recoveries across trust claims, litigation and VA benefits typically fall in the $1.5–3 million range; VA disability rated at 100% for mesothelioma. Figures are qualified process descriptions, not guarantees or predicted outcomes.

How Does Pleural Mesothelioma Compare to Peritoneal?

Pleural and peritoneal mesothelioma are the two most common forms of this asbestos-related cancer, but they differ significantly in location, demographics, treatment, and survival. Pleural mesothelioma develops in the pleura (lung lining) and accounts for approximately 80% of all diagnoses, while peritoneal mesothelioma arises in the peritoneum (abdominal lining) and represents roughly 7–30% of cases.

The demographic profiles diverge sharply. Pleural mesothelioma predominantly affects men (73% of cases) with a median age at diagnosis of 72–78 years, reflecting decades of occupational asbestos exposure in male-dominated industries. Peritoneal mesothelioma has a near-equal male-to-female ratio, a younger median age of 50–65 years, and a meaningful proportion of cases (20–40%) occur without documented asbestos exposure.

The most striking difference is in treatment outcomes. Pleural mesothelioma is primarily treated with chemotherapy and immunotherapy — cisplatin/pemetrexed plus nivolumab/ipilimumab or pembrolizumab — achieving median survival of 14–18 months. Peritoneal mesothelioma is treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), which has extended median survival to approximately 53 months in eligible patients. The overall 5-year survival rate reflects this gap: approximately 12% for pleural versus 30–50% for peritoneal disease with optimal treatment.

Feature	Pleural Mesothelioma	Peritoneal Mesothelioma
Location	Pleura (lung lining)	Peritoneum (abdominal lining)
Percentage of Cases	~80%	~7–30%
Annual U.S. Cases	~2,669	~800
Median Age at Diagnosis	72–78 years	50–65 years
Male-to-Female Ratio	3–4:1	~1:1
Primary Symptoms	Chest pain, dyspnea, pleural effusion	Abdominal pain, ascites, bloating
Primary Treatment	Chemotherapy and/or immunotherapy (± surgery)	CRS/HIPEC
Median Survival	14–18 months	~53 months (with CRS/HIPEC)
5-Year Survival	~12%	30–50% (optimal treatment)

What Is Pleural Mesothelioma?

Pleural mesothelioma is a malignant tumor that originates in the mesothelial cells lining the pleural membrane — the two-layered serous membrane that surrounds the lungs and lines the thoracic cavity. The pleura consists of two layers: the visceral pleura, which adheres directly to the lung surface, and the parietal pleura, which lines the inner chest wall. Between these layers lies a thin layer of lubricating fluid that allows the lungs to expand and contract smoothly during respiration.

When asbestos fibers are inhaled, they can travel through the respiratory tract and become embedded in the pleural tissue. Unlike most foreign particles, the body cannot effectively break down or expel these microscopic mineral fibers. Over time — typically 20 to 50 years — the persistent presence of asbestos fibers triggers a cascade of biological events including chronic inflammation, oxidative stress, DNA damage, and impairment of tumor suppressor genes such as BAP1, NF2, and CDKN2A. This molecular damage ultimately leads to uncontrolled cell proliferation and tumor formation.

The tumor typically begins as small nodules scattered across the pleural surface and progressively grows to encase the lung in a rind-like fashion. As the disease advances, it may invade the underlying lung parenchyma, chest wall, diaphragm, pericardium, and mediastinal structures. Pleural effusion — the accumulation of fluid between the pleural layers — is among the earliest manifestations and is present at diagnosis in the large majority of patients: in a SEER cohort of 3,384 US patients diagnosed between 2010 and 2017, only 10.79% lacked pleural effusion at diagnosis.

Unlike lung cancer, which typically forms a discrete mass within the lung tissue, pleural mesothelioma grows as a diffuse, sheet-like tumor along the pleural surfaces. This diffuse growth pattern makes complete surgical resection exceptionally challenging and contributes to the disease's poor prognosis.

How Common Is Pleural Mesothelioma?

According to the most recent CDC U.S. Cancer Statistics data, 2,669 new mesothelioma cases were reported in the United States in 2022, the latest year with complete population-level registry data. The American Cancer Society estimates approximately 3,000 new cases are diagnosed annually. Between 2003 and 2022, a total of 63,620 mesothelioma cases were reported in the U.S.

The age-adjusted incidence rate has been declining steadily — from 1.08 per 100,000 in 2003 to 0.65 per 100,000 in 2022 — reflecting the phased reduction in asbestos use that began in the 1970s. However, due to the disease's exceptionally long latency period, new cases continue to emerge decades after exposure cessation. Approximately 2,236 Americans died from mesothelioma in 2022.

Pleural mesothelioma disproportionately affects men over the age of 65. The National Cancer Database analysis of 41,074 patients (2004–2020) found that 73.2% were male and 26.8% female, yielding a male-to-female ratio of approximately 2.7:1 to 3.8:1 depending on the registry. The median age at diagnosis ranges from 72 to 78 years across different data sources. Most patients (33.5%) were diagnosed between ages 71 and 80, and 23.1% were over age 80.

The gender disparity reflects historical patterns of occupational asbestos exposure concentrated in male-dominated industries including construction, shipbuilding, manufacturing, and military service. Notably, women tend to have better survival outcomes: a SEER analysis of 14,228 pathologically confirmed cases found 5-year survival of 13.4% in women versus 4.5% in men (p < 0.0001), an advantage that persisted after adjustment for age, stage, race, and treatment (hazard ratio 0.78; 95% CI 0.75–0.82).

Globally, mesothelioma incidence varies dramatically by country, correlating with historical asbestos consumption patterns. The United Kingdom, Australia, Italy, and the Netherlands report among the highest per-capita rates. Many developing nations are expected to see rising rates in coming decades as the latency period unfolds following continued asbestos use.

What Are the Signs and Symptoms?

The signs and symptoms of pleural mesothelioma are often nonspecific and insidious, closely mimicking those of more common respiratory conditions such as pneumonia, chronic obstructive pulmonary disease, or lung cancer. This diagnostic ambiguity frequently results in delays of 3 to 6 months between initial symptom presentation and definitive diagnosis.

Early symptoms (Stage I–II) typically include persistent dry cough that does not respond to standard treatments, shortness of breath (dyspnea) that gradually worsens, chest pain that may be dull or pleuritic in nature, and unexplained fatigue or general malaise. Because these presenting symptoms are nonspecific, many patients initially attribute them to aging or pre-existing conditions.

Progressive symptoms (Stage III–IV) may include significant weight loss (often 10% or more of body weight), night sweats and low-grade fever, increasing difficulty breathing at rest, dysphagia (difficulty swallowing) if the tumor compresses the esophagus, and a palpable chest wall mass. In advanced disease, patients may develop superior vena cava syndrome if the tumor obstructs the major vein returning blood from the upper body, or pericardial effusion if the cancer extends to the heart lining.

Pleural effusion is the most common presenting finding: in a SEER cohort of 3,384 US patients diagnosed with pleural mesothelioma between 2010 and 2017, only 10.79% lacked pleural effusion at diagnosis. The accumulation of fluid in the pleural space compresses the lung and significantly impairs breathing. While thoracentesis (fluid drainage) can provide temporary relief, the effusion typically recurs without definitive treatment such as pleurodesis or an indwelling pleural catheter.

Anyone with a history of asbestos exposure who develops persistent respiratory symptoms should inform their physician of their exposure history, as this information is critical for guiding appropriate diagnostic workup. Early detection, while the disease remains at a lower stage, offers the best opportunity for effective treatment: NCI's PDQ treatment summary sets out separate treatment options for localized versus advanced pleural mesothelioma.

How Is Pleural Mesothelioma Diagnosed?

Diagnosing pleural mesothelioma is a multi-step process that combines imaging studies, tissue sampling, and sophisticated laboratory analysis. The diagnostic pathway is complex because mesothelioma can closely resemble several other conditions, including lung adenocarcinoma, reactive mesothelial hyperplasia, and various metastatic cancers involving the pleura.

Imaging Studies

The diagnostic workup typically begins with a chest X-ray, which may reveal unilateral pleural effusion, pleural thickening, or a pleural-based mass. Contrast-enhanced CT is the modality of choice for initial evaluation of suspected pleural mesothelioma, providing detailed visualization of tumor extent, pleural thickening patterns, and involvement of adjacent structures. CT alone cannot establish the diagnosis: diffuse or nodular pleural thickening is suggestive of mesothelioma, particularly when it involves the mediastinal pleura, but tissue is still required.

PET-CT has a narrower role than is often assumed, particularly for nodal staging. The ERS/ESTS/EACTS/ESTRO guidelines state that FDG-PET is limited in the assessment of nodal stage, because uptake in the immediately adjacent diseased pleura masks nodal signal. Reported sensitivity is 38% for N1 and 67% for T4 disease. Prior talc pleurodesis further distorts FDG uptake and SUVmax measurement, and PET-CT is not specific enough to diagnose mesothelioma routinely. Where PET-CT does add value is in identifying occult distant metastatic disease, and in higher specificity for stage II and stage III disease compared with CT alone. MRI is most useful at the margins of disease — at the apex around the subclavian vessels and inferiorly around the diaphragm — to demonstrate multifocal chest wall invasion when radical surgery is being considered.

For follow-up after active treatment, CT is the modality in routine use. The European guidelines are explicit that no evidence-based follow-up recommendation exists in mesothelioma. The task force suggests a chest/abdominal CT scan every 3–6 months after active treatment, with monitoring of disease progression otherwise guided by signs and symptoms during clinical follow-up. The role of periodic imaging surveillance — whether by CT, MRI or PET — is designated a research priority rather than settled practice.

Tissue Biopsy

A definitive diagnosis of pleural mesothelioma requires tissue biopsy — fluid cytology alone is insufficient for reliable diagnosis, with a sensitivity of only approximately 30–50%. The preferred biopsy approaches include thoracoscopy (video-assisted thoracoscopic surgery, or VATS), which allows direct visualization of the pleural surfaces and targeted biopsy under direct vision, and CT-guided core needle biopsy for lesions accessible percutaneously. VATS biopsy is generally preferred because it provides larger tissue samples, allows assessment of tumor extent, and can be combined with pleurodesis for effusion control.

Immunohistochemistry (IHC)

Once tissue is obtained, immunohistochemical staining is essential for distinguishing mesothelioma from other malignancies. The standard IHC panel includes positive markers for mesothelioma (calretinin, WT1, CK5/6, D2-40/podoplanin) and negative markers that help exclude adenocarcinoma (CEA, TTF-1, claudin-4, Ber-EP4). Loss of BAP1 expression, detected by immunohistochemistry, is found in approximately 60–70% of epithelioid mesotheliomas and is virtually absent in reactive mesothelial proliferations, making it a valuable diagnostic adjunct. The ERS/ESTS/EACTS/ESTRO guidelines note that standard staining procedures are insufficient in approximately 10% of cases, justifying specific markers — including BAP1 and CDKN2A (p16) — to separate atypical mesothelial proliferation from malignant mesothelioma. The same ~10% figure, and the same recommendation to fall back on specific immunohistochemical markers, appeared in the predecessor 2010 ERS/ESTS guidelines.

The panel does not perform equally across histological subtypes. This matters most in sarcomatoid disease, which frequently fails to express the conventional mesothelial markers. Calretinin is expressed in about 82% of pleural mesotheliomas overall but in only 48% of sarcomatoid cases in a 147-patient series. In a separate series of 17 sarcomatoid mesotheliomas, calretinin was positive in 52.9% and WT-1 in 64.7%, and the combined calretinin-positive/WT1-positive pattern carried a sensitivity of only 23.5% — so a negative mesothelial panel does not exclude the diagnosis.

BAP1 behaves the same way. In a 111-case tissue microarray, BAP1 expression was lost in 77% of epithelioid tumours and 49% of biphasic tumours, but was retained in all 10 sarcomatoid cases; all 20 non-neoplastic mesothelial specimens also retained it, giving BAP1 loss 100% specificity but only 61% sensitivity for malignancy. Retained nuclear BAP1 staining therefore carries little diagnostic weight in a spindle-cell lesion. In that setting pathologists rely on cytokeratin positivity, and on markers such as GATA3 — positive in 70.6% of sarcomatoid mesotheliomas versus 16.7% of lung sarcomatoid carcinomas — to separate sarcomatoid mesothelioma from lung sarcomatoid carcinoma and from organising pleuritis.

Biomarkers

Soluble mesothelin-related peptides (SMRP/MESOMARK) remain the only FDA-approved serum biomarker for mesothelioma, approved in 2007 primarily for monitoring disease progression rather than initial diagnosis. Meta-analyses report a pooled sensitivity of approximately 61% and specificity of 87%. Emerging biomarkers including fibulin-3, HMGB1, and DNA methylation-based liquid biopsy approaches show promise for early detection, particularly in multi-biomarker panels that achieve sensitivities exceeding 90%.

What Are the Histological Subtypes?

Pleural mesothelioma is classified into three primary histological subtypes according to the WHO Classification of Tumors (updated 2021), and the subtype is one of the strongest independent prognostic factors for survival.

Epithelioid Mesothelioma

The epithelioid subtype is the most common, accounting for 60–70% of all pleural mesotheliomas. Characterized by polygonal or oval-shaped cells forming clusters, sheets, or tubular structures, it carries the most favorable prognosis of the three subtypes. Median overall survival ranges from 12 to 27 months depending on treatment, with 2-year survival rates of 28–45% in surgically treated patients. The epithelioid subtype responds best to platinum/pemetrexed chemotherapy and is the primary candidate for surgical intervention. Within this subtype, the tubulopapillary architectural pattern carries the best prognosis, while the solid and micropapillary patterns are associated with more aggressive behavior.

The 2021 WHO classification introduced formal nuclear grading for epithelioid mesothelioma based on mitotic count and nuclear atypia. High-grade tumors carry a hazard ratio of 3.09 for overall survival compared to low-grade tumors, making the grading system an important prognostic tool.

Biphasic (Mixed) Mesothelioma

The biphasic subtype accounts for 10–20% of cases and contains both epithelioid and sarcomatoid components, with a minimum of 10% of each required for diagnosis on resection specimens. Median survival ranges from 8 to 13 months. Prognosis within this subtype varies significantly depending on the proportion of sarcomatoid component — tumors with a sarcomatoid-predominant pattern behave more aggressively. Approximately 20% of biopsies initially showing epithelioid morphology will reveal biphasic features in full resection specimens, suggesting this subtype may be underdiagnosed on initial biopsy.

Sarcomatoid Mesothelioma

The sarcomatoid subtype accounts for 10–20% of cases and is characterized by spindle-shaped cells resembling sarcoma. It carries the worst prognosis, with median survival of 4 to 8 months. Sarcomatoid mesothelioma responds poorly to standard chemotherapy and is generally not considered a candidate for surgical resection. However, sarcomatoid disease falls within the non-epithelioid subgroup that has shown the most dramatic benefit from immunotherapy — in the CheckMate 743 trial, nivolumab plus ipilimumab produced a five-year overall survival of 12% versus 1% in non-epithelioid patients, sarcomatoid and biphasic combined (HR 0.48; 95% CI 0.33–0.68). The trial did not report an overall survival figure for sarcomatoid histology alone. A molecular analysis of 1,294 mesotheliomas — 980 of them pleural — found that among the pleural cases, non-epithelioid tumors express PD-L1 more often than epithelioid tumors (74% versus 51%, P = .02), with identical tumor mutational burden between the two groups (median 1.25 mutations/Mb). This is one proposed contributor to the differential immunotherapy benefit.

Transitional Mesothelioma

A newer recognized pattern, transitional mesothelioma is defined by cells that have lost some epithelioid features but are not overtly sarcomatoid. The 2021 WHO classification places this pattern under sarcomatoid mesothelioma. A landmark study by the MESOPATH Reference Center found that transitional mesothelioma had a median survival of just 6.7 months and 0% 5-year survival, with molecular profiling showing it clusters with sarcomatoid rather than epithelioid disease.

How Is Pleural Mesothelioma Staged?

Pleural mesothelioma uses the TNM 8th Edition staging system (AJCC/UICC), which classifies the disease based on three components: T (tumor extent), N (regional lymph node involvement), and M (distant metastasis).

Stage	Description	5-Year Survival
Stage I	Tumor confined to ipsilateral parietal pleura (IA) or involving visceral pleura (IB). No lymph node involvement.	18–20%
Stage II	Tumor involving all ipsilateral pleural surfaces with at least one of: invasion into diaphragmatic muscle or pulmonary parenchyma.	~12%
Stage III	Locally advanced disease. May involve chest wall, mediastinal fat, pericardium, or ipsilateral lymph nodes (IIIA: resectable; IIIB: unresectable).	~14%
Stage IV	Distant metastasis or contralateral pleural involvement. Includes spread to brain, bones, liver, or contralateral lung.	7–8%

Accurate staging is critical for determining treatment eligibility, particularly for surgery. PET-CT is increasingly recommended for preoperative staging, as it improves detection of mediastinal lymph node involvement and distant metastases that may preclude surgical intervention. The NCCN 2025 guidelines emphasize that surgery should only be considered for patients with early-stage (Stage I) disease confirmed to be node-negative, representing a significant narrowing of surgical candidacy compared to earlier recommendations.

What Treatment Options Are Available?

Treatment for pleural mesothelioma typically involves a multimodal approach combining surgery, chemotherapy, radiation therapy, and/or immunotherapy. Treatment selection depends on disease stage, histological subtype, patient performance status, and institutional expertise. The past five years have seen transformative advances, particularly with the FDA approval of two immunotherapy-based regimens.

Surgery

Surgical intervention for pleural mesothelioma remains controversial following the 2024 MARS 2 trial results. The two primary curative-intent procedures are:

Pleurectomy/Decortication (P/D): This lung-sparing procedure removes the parietal and visceral pleura while preserving the underlying lung. Extended P/D (EPD) additionally resects the pericardium and/or diaphragm. P/D is now the preferred surgical approach when surgery is performed, carrying perioperative mortality of approximately 3% at high-volume centers compared to 5–7% for EPP.

Extrapleural Pneumonectomy (EPP): This radical procedure removes the entire pleura, the ipsilateral lung, pericardium, and diaphragm. Once the standard surgical approach, EPP has largely fallen out of favor following the MARS trial (2011), whose authors concluded that radical surgery in the form of EPP within trimodal therapy "offers no benefit and possibly harms patients" — the hazard ratio for overall survival between the EPP and no-EPP groups was 1.90 (95% CI 0.92–3.93, p=0.082), and there were ten serious adverse events in the EPP group against two in the no-EPP group — and the subsequent shift in expert consensus toward lung-sparing techniques.

The MARS 2 trial (2024), a landmark Phase 3 randomized controlled trial across 26 UK hospitals, found that EPD plus chemotherapy resulted in worse survival than chemotherapy alone — median OS of 19.3 months in the surgery group versus 24.8 months with chemotherapy alone. The surgery group also experienced 3.6 times more serious adverse events. The current NCCN guidelines recommend surgery only for early-stage (Stage I), node-negative, epithelioid disease at experienced centers.

The surgical decision is best framed as one question: is macroscopic complete resection achievable? Macroscopic complete resection (MCR) means removing all visible tumour while accepting that microscopic disease remains. It has been the stated goal of primary surgery within multimodality therapy since 2006, and it is what distinguishes a cytoreductive operation from a palliative one. If MCR is achievable, the next question is whether P/D or EPP is the procedure that achieves it. If it is not achievable, the operation is palliative, and describing it as such matters for what a patient should expect from it.

"Is macroscopic complete resection achievable or not? If yes, can this goal be achieved with P/D or EPP? Therein lies the rub."
— Luciano Mutti, MD, PhD, Professor of Oncology, UniCamillus, Rome; President, GIMe (Italian Mesothelioma and Environmental Oncology Group); co-author, ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma, in expert review of this page

MARS 2's interpretation is contested. A 2025 perspective in the Journal of Thoracic Oncology deliberately assembled internationally recognised experts who agreed with the trial's conclusion alongside those who found issues with its conduct, and reported that there has been no unanimity in the mesothelioma surgical community. The points at issue include the timing of randomisation, quality assurance, selection of histological subtypes, the use of preoperative staging, the statistical methods, and the reasons for surgical mortality. Its authors suggest the interpretation of MARS 2 may play an important role in modulating the role of surgery in future, rather than having settled it.

Chemotherapy

Cisplatin plus pemetrexed has been the standard first-line chemotherapy regimen since the EMPHACIS trial led to FDA approval in 2004. This combination achieves a median overall survival of approximately 12–16 months, with response rates of 40–45%. Carboplatin may be substituted for cisplatin in patients who cannot tolerate the latter. Chemotherapy is administered for up to 6 cycles, with each cycle lasting 21 days.

The epithelioid subtype responds significantly better to platinum/pemetrexed chemotherapy than non-epithelioid subtypes. In a real-world cohort, patients with epithelioid tumors receiving cisplatin plus pemetrexed achieved median OS of 30.7 months versus 17.2 months for non-epithelioid patients.

Immunotherapy

Immunotherapy has transformed the treatment landscape for pleural mesothelioma, with two FDA-approved regimens now available:

Nivolumab + Ipilimumab (CheckMate 743): Approved October 2020, this dual immune checkpoint inhibitor combination targeting PD-1 and CTLA-4 achieved median overall survival of 18.1 months versus 14.1 months for chemotherapy alone (HR 0.74). The benefit is most pronounced in non-epithelioid disease, where five-year overall survival was 12% versus 1% at five years (HR 0.48; 95% CI 0.33–0.68) versus chemotherapy. At extended follow-up, five-year overall survival rates were 14% versus 6%. The NCCN now recommends nivolumab + ipilimumab as first-line treatment for non-epithelioid (sarcomatoid and biphasic) mesothelioma.

Pembrolizumab + Pemetrexed + Platinum (KEYNOTE-483): Approved September 2024, this combination of anti-PD-1 immunotherapy with standard chemotherapy achieved median OS of 17.3 months versus 16.1 months for chemotherapy alone, with a 3-year overall survival rate of 25% versus 17%. The objective response rate was 52% versus 29%. This regimen provides the first option combining immunotherapy with chemotherapy, offering particular benefit for patients with non-epithelioid histology.

Radiation Therapy

Radiation therapy in pleural mesothelioma serves primarily as a palliative or adjuvant modality rather than a curative treatment on its own. Intensity-modulated radiation therapy (IMRT) may be used after pleurectomy/decortication in selected patients to reduce local recurrence. The 2025 NCCN guidelines note that IMRT is no longer recommended following EPP. Palliative radiation remains appropriate for pain control, particularly for chest wall pain or procedure-tract metastases.

Emerging Therapies

Several promising therapies are in clinical development:

CAR-T Cell Therapy: Chimeric antigen receptor T-cell (CAR-T) therapy targeting mesothelin — a surface protein overexpressed in approximately 66% of epithelioid mesotheliomas — represents one of the most promising emerging immunotherapies for pleural mesothelioma. Unlike checkpoint inhibitors that "release the brakes" on existing immune responses, CAR-T cells are a patient's own T cells genetically engineered to recognize and destroy cancer cells directly, functioning as a "living drug" that can persist, expand, and provide ongoing tumor surveillance. This remains an exploratory approach in mesothelioma. The evidence is a phase I trial with a phase II ongoing; there is no randomised comparison against any standard of care, and no CAR-T product is approved for mesothelioma or for any solid tumour.

The landmark Phase I trial at Memorial Sloan Kettering Cancer Center (NCT02414269), led by Dr. Prasad Adusumilli, treated 27 patients with intrapleurally delivered mesothelin-targeted CAR-T cells. In a subset of 11 patients receiving CAR-T plus pembrolizumab, the overall response rate was 72%, including 2 complete metabolic responses and 6 partial responses. Among 16 patients who received lymphodepleting chemotherapy, 12-month overall survival was 80.2% and best overall response rate was 63%. Critically, PD-L1 expression did not predict response — 6 of 8 responses occurred in PD-L1-low patients, suggesting CAR-T therapy may benefit patients unlikely to respond to checkpoint inhibitors alone.

A key innovation of the MSKCC program is intrapleural delivery — administering CAR-T cells directly into the pleural cavity rather than intravenously. Preclinical studies demonstrated that intrapleurally delivered CAR-T cells "vastly outperformed" systemically infused cells, achieving superior activation, tumor eradication, and persistence. Intrapleurally delivered cells also circulated systemically and controlled tumors at distant sites, functioning through a "regional distribution center" model. This approach exploits the unique anatomy of pleural mesothelioma as a surface-based malignancy accessible to local therapy.

The next-generation MSKCC trial (NCT04577326) is evaluating M28z1XXPD1DNR — a CAR engineered with a PD-1 dominant-negative receptor that acts as a built-in decoy, preventing T-cell exhaustion without requiring concurrent anti-PD-1 antibody therapy. Additional actively recruiting trials include NCI's TNhYP218 (NCT06885697), which targets a novel membrane-proximal mesothelin epitope; CAR.70 + NK cells at MD Anderson (NCT05703854); and SynKIR-110, a novel KIR-CAR construct being evaluated at Penn, MD Anderson, Kansas, and Wisconsin. As of January 2026, 5 CAR-T clinical trials are actively recruiting mesothelioma patients, though no mesothelioma CAR-T program has yet advanced beyond Phase I/II. For full details, see CAR-T_Cell_Therapy.

Tumor Treating Fields (TTFields): The Optune Lua device (formerly NovoTTF-100L) delivers low-intensity alternating electric fields through arrays worn on the chest, intended to disrupt cancer cell division. It reached the US market through the FDA's Humanitarian Device Exemption pathway, which requires a demonstration of safety and probable benefit rather than proven effectiveness.

The evidence base is a single trial. STELLAR (Ceresoli et al., Lancet Oncology, 2019) enrolled 80 patients with unresectable pleural mesothelioma and reported median overall survival of 18.2 months (95% CI 12.1–25.8) with TTFields added to pemetrexed and platinum chemotherapy. The trial was prospective, single-arm and industry-funded, with no control group — so that figure cannot be compared against what the same patients would have achieved on chemotherapy alone. Its investigators concluded that "further investigation in a randomised trial is warranted"; no randomised trial has reported since.

The 2025 ASCO Guideline Update addresses TTFields directly. Recommendation 4.5 states that there is insufficient evidence to make a recommendation on adding TTFields to pemetrexed plus platinum chemotherapy, rating the quality of evidence very low and leaving the strength of recommendation not rated.

STELLAR also drew a published critique in Lancet Oncology. Barbarino and colleagues argued the single-arm design and patient mix made the survival figure hard to interpret, pointing to probable lead-time bias, absent asbestos-exposure and staging detail, and an unusually high proportion of patients with ECOG performance status 0 — 56% — which is uncommon in mesothelioma and independently predicts longer survival. They further noted that patients were not stratified by mitotic index or other proliferation markers, though disrupting mitosis is the treatment's proposed mechanism. The STELLAR investigators published a reply.

In safety terms TTFields is well tolerated: skin irritation beneath the arrays was the only adverse event attributed to the device, and STELLAR recorded no treatment-related deaths. What remains unestablished is whether it extends survival.

Hyperthermic Intrathoracic Chemotherapy (HITHOC): This technique circulates heated chemotherapy through the chest cavity immediately after cytoreductive surgery. A large National Cancer Database analysis of 3,232 patients showed that HITHOC was independently associated with improved overall survival (20.5 vs. 16.8 months; HR 0.80), with the greatest benefit seen in epithelioid patients.

NCCN Clinical Practice Guidelines (2025–2026)

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Malignant Pleural Mesothelioma were substantially revised in 2025–2026, representing the most consequential guideline changes since the approval of pemetrexed in 2003. The current Version 3.2026 (July 8, 2026) carries forward structural changes from Version 1.2025, which was presented at the NCCN Annual Conference in March 2025 by Dr. James Stevenson of the Cleveland Clinic. The parallel ASCO 2025 Guideline Update (published in the Journal of Clinical Oncology, drawing on 110 peer-reviewed studies from 2016–2024) is largely concordant with NCCN recommendations.

Histology-Driven First-Line Therapy: The NCCN guidelines stratify first-line systemic therapy by histologic subtype, but immunotherapy is a preferred Category 1 option in both arms — histology shifts emphasis, not exclusion:

• Non-epithelioid (sarcomatoid/biphasic): Nivolumab + ipilimumab and platinum/pemetrexed + pembrolizumab are the preferred first-line regimens (Category 1); platinum/pemetrexed alone is an other-recommended option. This reflects the CheckMate 743 finding that five-year overall survival in non-epithelioid disease was 12% versus 1% (HR 0.48; 95% CI 0.33–0.68).
• Epithelioid: NCCN lists four Category 1 preferred first-line options — platinum/pemetrexed, platinum/pemetrexed + bevacizumab, platinum/pemetrexed + pembrolizumab, and ipilimumab + nivolumab. This reflects the more modest CheckMate 743 benefit in epithelioid patients (median OS 18.2 vs. 16.7 months; HR 0.85) alongside the September 2024 FDA approval of pembrolizumab + pemetrexed + platinum.

Revised Surgical Guidance: Surgery should only be considered for patients with early-stage (clinical Stage I) disease limited to the pleura with no lymph node involvement. Histology must be epithelioid — sarcomatoid mesothelioma patients should not be offered maximal surgical cytoreduction. Pleurectomy/decortication (P/D) is NCCN's preferred surgical treatment option over extrapleural pneumonectomy (EPP), though NCCN cautions that for early-stage epithelioid disease it remains unclear whether P/D benefits patients over systemic therapy alone. Separately, a 2025 meta-analysis of 24 retrospective studies associated P/D with longer overall survival than EPP (mean difference 7.01 months; 95% CI 1.15–12.86), with substantial heterogeneity (I²=98.5%). This comparison does not establish superiority over systemic therapy alone. IMRT is no longer recommended post-EPP. For how a 2026 international expert panel addressed the same surgical questions through a modified Delphi process — and what that panel explicitly declined to claim — see Society of Thoracic Surgeons 2026 Expert Consensus on Pleural Mesothelioma.

Biomarker Guidance: PD-L1, TMB, and MSI status should not be used to guide treatment selection. Histologic subtype (epithelioid vs. non-epithelioid) remains the primary driver of treatment decisions. ASCO's 2025 guideline update, Recommendation 7.1, states that all patients with mesothelioma should be offered germline testing (evidence quality High; strength of recommendation Strong).

How Should These Trial Results Be Interpreted?

The regimens above are guideline-recommended and those recommendations are not in dispute. What is contested in the peer-reviewed literature — by groups including co-authors of the European guidelines — is how robust the underlying trial evidence is. Four limitations matter when comparing survival figures across trials.

Progression-free survival is not a validated surrogate for overall survival in mesothelioma. An Alliance analysis pooling 17 phase II trials and 716 patients found only low-to-moderate individual-level correlation between PFS and OS (Kendall's tau 0.46–0.47), with summary-level surrogacy varying widely depending on the risk factor examined. The authors concluded there is no evidence that PFS is a valid surrogate endpoint for OS in malignant mesothelioma. A regimen that improves PFS has therefore not thereby been shown to extend life.

The frontline trials are statistically fragile, and CheckMate 743's censoring pattern favoured the control arm. A 2022 comparative-effectiveness analysis of the three frontline randomised trials — EMPHACIS (referred to in that analysis as the Mesothelioma Cisplatin Pemetrexed Study), MAPS and CheckMate 743, 1,501 patients in total — found no statistically significant overall-survival difference between MAPS and CheckMate 743 (HR 0.97; 95% CI 0.79–1.20; p=0.79), despite MAPS having enrolled patients with worse prognosis. The survival-inferred fragility index was under 1% of total sample size in all three trials. Reverse restricted-mean-survival-time analysis showed differential censoring in CheckMate 743 favouring the control group, both in the intention-to-treat population (0.56; 95% CI 0.18–0.94; p=0.004) and in the non-epithelioid subgroup (0.90; 95% CI 0.001–1.79; p=0.048). The same group has since published a dedicated analysis of methodological fragility and censoring bias in the five-year CheckMate 743 update. A separate reconstruction of individual patient data across four trials found nivolumab + ipilimumab and bevacizumab + pemetrexed + cisplatin produced essentially the same overall-survival benefit over chemotherapy (HR 0.79 for both), concluding that the newer agents deliver a small though significant improvement rather than a step change.

The non-epithelioid result is a subgroup finding, not a trial designed to test it. CheckMate 743 stratified but was not powered on histology, so the 12%-versus-1% five-year figure is a subgroup analysis. Under good clinical practice such a result is hypothesis-generating — it justifies a dedicated randomised trial in non-epithelioid disease rather than settling the question. No such confirmatory trial has reported.

"As for GCP, the current results on non-epithelial are only “hypothesis generating” and not set in stone. That said, ICIs are likely to improve the prognosis of these patients, but we still lack a rigorous confirmative study."
— Luciano Mutti, MD, PhD, in expert review of this page

Comparator choice is a recurring criticism in the relapsed setting. CONFIRM, the phase III trial supporting second-line nivolumab, randomised patients against placebo rather than against an active agent, reporting median OS of 10.2 versus 6.9 months (HR 0.69). Published critiques argue that where a comparator is weaker than the treatment a patient would actually be offered — an active second-line drug, or rechallenge with a first-line regimen — the measured benefit overstates the clinical gain, and that disease control rate is a particularly weak endpoint given it does not track overall survival in this disease.

"Any intervention arm should be compared with the optimal control arm."
— Luciano Mutti, MD, PhD, in expert review of this page

None of this is an argument against treatment. It is an argument for reading a hazard ratio together with the population it was measured in, the arm it was measured against, and the endpoint it was measured on.

What Happens When Pleural Mesothelioma Recurs?

Recurrence after first-line treatment is nearly universal in pleural mesothelioma. In the EMPHACIS trial, median time to progression on cisplatin plus pemetrexed was 5.7 months, against 3.9 months for cisplatin alone. Recurrence patterns vary by treatment type and histological subtype.

Recurrence Patterns

Pleural mesothelioma recurs locally in the ipsilateral chest in the majority of cases, reflecting its pattern of diffuse pleural spread rather than distant metastasis. Local recurrence dominates after both surgery and systemic therapy. Distant recurrence — to the contralateral lung, peritoneum, liver, or bone — occurs in a minority of patients, though rates increase with sarcomatoid and biphasic histologies. After surgical resection, local recurrence rates range from 50–80% even with macroscopic complete resection, typically within the first year.

Second-Line Treatment Options

The choice of second-line therapy depends on what was used first-line and the duration of initial response. For the full relapsed-setting evidence — including the RAMES trial's 70% confidence-interval caveat, the terminated nivolumab-ramucirumab HCRN trial, the negative anetumab ravtansine trial, and ASCO/ESMO guideline positioning — see Second-Line_Systemic_Therapy_for_Pleural_Mesothelioma.

After first-line chemotherapy:

• Gemcitabine + ramucirumab — The RAMES phase II RCT demonstrated median OS of 13.8 months versus 7.5 months with gemcitabine alone, establishing the first significant OS benefit in second-line pleural mesothelioma (HR 0.71). Benefit was independent of age, histology, and time to first-line progression. A published critique in Lancet Oncology questions whether VEGF inhibition has a demonstrated role in mesothelioma at all, and a broader analysis from the same group argues that several recently proposed mesothelioma regimens raise concerns about trial design and comparator choice — see how these results should be read.
• Oral vinorelbine — The VIM phase II RCT showed median PFS of 4.2 months versus 2.8 months with active symptom control alone (HR 0.59; p=0.0017), supporting vinorelbine as the most accessible salvage option.
• Nivolumab ± ipilimumab — In the MAPS-2 trial, 12-week disease control was achieved in 44% (24/54) of patients on nivolumab and 50% (27/54) on nivolumab plus ipilimumab in the primary analysis population, meeting the trial's pre-specified 40% threshold. MAPS-2 enrolled patients progressing after first- or second-line pemetrexed–platinum, supporting checkpoint inhibitors in the second- or third-line setting.

After first-line immunotherapy (nivolumab + ipilimumab):

• Pemetrexed + platinum ± bevacizumab — A 2025 Japanese retrospective study of 43 patients who received pemetrexed–platinum after first-line nivolumab–ipilimumab reported median overall survival of 17.1 months and median progression-free survival of 5.7 months; among patients with measurable disease, the overall response rate was 30.3% and the disease control rate 69.7%. The authors concluded these outcomes are similar to those seen with pemetrexed–platinum in the first-line setting, supporting it as a reasonable second-line option after immunotherapy.

Pemetrexed rechallenge: Retrospective series suggest that patients who achieved a partial response or stable disease on first-line pemetrexed–platinum and then had a treatment-free interval of at least six months may benefit from pemetrexed rechallenge, with disease control rates of 48–66% reported. Response rates on rechallenge are lower than those seen with initial therapy — 17% and 19% in the two largest series, against a 50% partial-response rate on first-line therapy within the same rechallenged cohort — so the benefit is better described as disease stabilisation than as a repeat response. One series recommends reserving rechallenge for patients whose first-line disease control lasted more than 12 months.

Clinical Trials at Progression

Enrollment in clinical trials is the preferred option at disease progression per ASCO 2025 guidelines. Actively recruiting trials include TEAD inhibitors targeting the Hippo/YAP pathway, mesothelin-targeted CAR-T cell therapy, and bispecific antibody constructs. The lead TEAD inhibitor, VT3989, enrolled on refractory solid tumour status rather than on NF2 status, and its phase 1/2 results are now published — see targeted therapies. See Clinical_Trials and Mesothelioma_Treatment_Options for current trial listings.

What Nutritional Support Is Available During Treatment?

Malnutrition is a critical and underrecognized challenge in pleural mesothelioma. Unlike many solid tumors where cachexia emerges in advanced stages, MPM patients frequently present at diagnosis already nutritionally compromised. The prognostic nutritional index (PNI) is an independently validated survival predictor: patients with PNI <44.6 face a hazard ratio for death of 2.29 (95% CI 1.415–3.706; p=0.001) compared to those with adequate nutritional status, with median overall survival of 11 months versus 18 months.

Mandatory Supplementation with Pemetrexed

Folic acid and vitamin B12 supplementation is a mandatory pharmaceutical protocol requirement — not optional — for all patients receiving pemetrexed-based chemotherapy. The established reason is toxicity reduction. In the pivotal EMPHACIS trial, supplementation was introduced after the first 117 patients had enrolled, and the trial reported that adding folic acid and vitamin B12 significantly reduced toxicity without adversely affecting survival time.

A separate phase II study of single-agent pemetrexed (n=64) reported that the 43 supplemented patients had a median overall survival of 13.0 months against 8.0 months for the 21 who were not supplemented — a five-month difference — and tolerated treatment better. That comparison was not randomised: supplementation was added by protocol amendment partway through the study, and supplemented patients completed a median of six cycles against two. The survival gap therefore reflects treatment exposure as well as the vitamins, and should not be read as a five-month survival benefit caused by supplementation.

Supplement	Protocol	Timing
Folic acid	350–1,000 mcg/day orally	Begin 7 days before first pemetrexed dose; continue throughout treatment and 21 days after final dose
Vitamin B12	1,000 mcg intramuscularly	One injection before first dose, then every 9 weeks (every 3 cycles)

Protein and Caloric Targets

The ESPEN Practical Guideline on Clinical Nutrition in Cancer (2021) — the most comprehensive applicable framework — recommends 25–30 kcal/kg/day total energy and 1.2–1.5 g protein/kg/day for cancer patients generally. Patients anticipating surgery should aim for 1.5–2.0 g/kg/day during prehabilitation. ESPEN's guidance is not mesothelioma-specific, and no mesothelioma-specific protein target has been established in a published cohort.

Diet and Immunotherapy Response

Since nivolumab + ipilimumab is now first-line standard for non-epithelioid MPM, the possible relationship between diet and immunotherapy efficacy has attracted interest — but the evidence base sits entirely outside mesothelioma, and the paragraph below should be read with that in mind. A JAMA Oncology cohort study of patients treated for advanced melanoma found that higher adherence to a Mediterranean dietary pattern was associated with improved response to immune checkpoint blockade. A separate melanoma cohort linked dietary fiber and probiotic intake to checkpoint-blockade response, and a 2025 systematic review reported that high dietary fiber intake was associated with an odds ratio of 5.79 for improved immunotherapy response in prospective cohorts. Every one of these findings comes from melanoma populations; no mesothelioma cohort has tested whether diet modifies checkpoint-inhibitor response, so these results are suggestive for MPM rather than established in it.

Supplements to Avoid During Treatment

High-dose antioxidants (vitamin C >1 g/day, vitamin E, beta-carotene) may reduce cisplatin and pemetrexed efficacy by neutralizing the reactive oxygen species that contribute to their cytotoxic mechanism. Beta-carotene is specifically contraindicated in patients with any smoking history due to the ATBC and CARET trials demonstrating increased lung cancer incidence. St. John's Wort, high-dose garlic, and ginseng alter CYP450 drug metabolism and should be avoided during active treatment.

When to Involve an Oncology Dietitian

Both ASCO and NCCN recommend multidisciplinary team management from diagnosis. Nutritional assessment belongs at diagnosis rather than at the point of visible wasting, and early referral matters most for patients experiencing pleural effusion-related early satiety, treatment-induced dysgeusia, or unintentional weight loss exceeding 5%. Mandatory folic acid and vitamin B12 supplementation alongside pemetrexed is a separate requirement, and its established purpose is reducing toxicity rather than extending survival.

What Palliative and Supportive Care Options Are Available?

Palliative care in pleural mesothelioma addresses the dominant symptom burden: pleural effusion — present at diagnosis in all but roughly one patient in ten — together with progressive dyspnoea and chest wall pain. Both ASCO and NCCN strongly recommend integration of palliative care from the time of diagnosis — not reserved for end-stage disease — based on evidence that early palliative care improves quality of life and, in some cancers, may extend survival.

Pleural Effusion Management

Malignant pleural effusion is the most common presenting symptom and the primary driver of dyspnea in MPM. Management options include:

• Therapeutic thoracentesis — Immediate symptom relief through pleural fluid drainage; typically recurs within 2–4 weeks, requiring repeated procedures
• Indwelling pleural catheter (IPC) — A tunneled catheter allowing home drainage on demand; preferred for patients with trapped lung or recurrent effusions who wish to avoid hospitalization
• Talc pleurodesis — Chemical fusion of pleural surfaces using talc slurry via chest tube or thoracoscopy; success rate of 60–80% but requires lung re-expansion and hospital stay

The choice depends on performance status, lung re-expansion potential, and patient preference regarding self-management versus hospital-based interventions.

Pain Management

Pleural mesothelioma pain is characteristically diffuse and neuropathic, reflecting chest wall invasion and intercostal nerve involvement. Management follows the WHO analgesic ladder, escalating from non-opioid analgesics through weak to strong opioids. Thoracic epidural analgesia provides superior pain control for diffuse chest wall involvement refractory to systemic opioids. Palliative radiation therapy is effective for localized chest wall pain and procedure-tract metastases.

Dyspnea Management

For breathlessness refractory to effusion drainage, low-dose opioids (morphine 2.5–5 mg oral every 4 hours) are the evidence-based intervention for symptomatic relief. Supplemental oxygen benefits patients with documented hypoxemia but does not improve dyspnea perception in normoxic patients. Positioning — upright or slightly forward-leaning — reduces diaphragmatic compression and improves ventilation in patients with residual effusions or chest wall restriction.

Phase-Specific Nutritional Goals in Palliative Care

As pleural mesothelioma progresses from active treatment through palliation to end-of-life care, nutritional goals must be recalibrated:

• Active treatment phase: Weight maintenance, muscle preservation, treatment completion — full caloric and protein targets (25–30 kcal/kg/day; 1.2–1.5 g protein/kg/day)
• Disease progression/palliative phase: Quality of life and comfort — relaxed targets guided by patient preference rather than prescriptive goals
• Terminal phase (days to weeks): Dignity and comfort — no artificial nutrition; short-term hydration only if reversible delirium is suspected

ESPEN 2021 consensus states: in terminal settings, the focus shifts to comfort, avoiding aggressive nutritional interventions that impose burden without benefit.

What Psychosocial Support Is Available for Patients and Caregivers?

The psychological burden of pleural mesothelioma extends beyond the patient to families and caregivers. A 2024 systematic review in BMJ Open found that 75% of mesothelioma caregivers report personal health impacts, and a companion mixed-methods survey of 96 patients and informal carers found 33.3% of participants — patients and carers together — screening positive for possible PTSD, carers scoring worse than patients, reflecting the occupational causation, rapid trajectory, and sense of industrial injustice inherent to this disease.

Patient Psychological Burden

Mesothelioma patients commonly experience anxiety, depression, and anger related to the preventable occupational or environmental nature of their exposure. The diagnosis frequently triggers acute distress involving legal urgency (statutes of limitations), financial concerns, and confrontation with poor prognosis statistics — all occurring simultaneously. Screening for psychological distress using validated tools (PHQ-9, GAD-7) should be integrated into routine multidisciplinary care.

Caregiver Support

Mesothelioma caregiving involves unique stressors: navigating complex multimodal treatment decisions, managing repeated hospital visits for effusion drainage, and witnessing rapid functional decline. Evidence-based support includes:

• Social workers embedded in mesothelioma multidisciplinary teams at specialized treatment centers
• Patient advocacy organizations offering peer support programs connecting families with others who have navigated the same diagnosis
• Online support communities providing 24-hour access to shared experience and practical guidance
• Palliative care teams addressing caregiver burnout alongside patient symptom management

Nutrition-Related Family Conflict

A common source of caregiver distress is conflict over food intake as disease progresses. Families must understand that loss of appetite in advanced mesothelioma is driven by tumor-induced cytokines — it is a consequence of the disease process, not a failure of caregiving. Forcing food increases patient distress without providing survival benefit. Palliative care teams and oncology dietitians should proactively address these expectations in family meetings, delivering the key message: not eating is not the cause of death.

For additional resources, see Emergency_Action_Checklist and Understanding_Your_Diagnosis.

What Is the Prognosis and Survival Rate?

The prognosis for pleural mesothelioma remains sobering, though survival outcomes have improved with advances in treatment. The overall 5-year relative survival rate is approximately 12% according to SEER data (2000–2020), making it one of the most lethal cancer types.

Prognostic Factor	Better Prognosis	Worse Prognosis
Histological Subtype	Epithelioid (median 12–27 months)	Sarcomatoid (median 4–8 months)
Stage at Diagnosis	Stage I (18–20% 5-year survival)	Stage IV (7–8% 5-year survival)
Gender	Female (13.4% 5-year survival)	Male (4.5% 5-year survival)
Age	Younger patients (<65)	Older patients (>75)
Performance Status	ECOG 0–1	ECOG 2+
Treatment	Multimodal therapy at specialized center	Best supportive care only

Several survival milestones have been achieved with modern treatment. The CheckMate 743 trial demonstrated that 28% of responders to nivolumab + ipilimumab maintained their response at 3 years, compared to 0% for chemotherapy — highlighting the durability advantage of immunotherapy. For selected surgical candidates with epithelioid histology, early-stage disease, and negative nodes, 5-year survival rates exceeding 20% have been reported — an outcome that is itself the argument for a continuing role for surgery in genuinely early disease, provided macroscopic complete resection is achievable.

Patients diagnosed with pleural mesothelioma should seek evaluation at specialized mesothelioma treatment centers with multidisciplinary teams experienced in this rare cancer. Access to clinical trials investigating emerging therapies may also provide additional treatment options.

How Does Asbestos Cause Pleural Mesothelioma?

The causal relationship between asbestos exposure and pleural mesothelioma is one of the most well-established in occupational medicine, supported by more than five decades of epidemiological, clinical, and molecular evidence.

The Mechanism of Disease

Asbestos is a group of naturally occurring mineral fibers classified into two families: serpentine (chrysotile, the most commonly used form) and amphibole (including crocidolite, amosite, tremolite, anthophyllite, and actinolite). When asbestos-containing materials are disturbed — through cutting, sanding, demolition, or natural deterioration — microscopic fibers become airborne and can be inhaled deep into the lungs.

Once inhaled, asbestos fibers migrate to the pleural space through several pathways: direct penetration through the lung tissue, transport via lymphatic channels, and passage through the visceral pleura at areas of high permeability. Amphibole fibers (particularly crocidolite and amosite) are considered more potent carcinogens for mesothelioma than chrysotile due to their needle-like shape and biopersistence — they resist breakdown by the body's defense mechanisms and can persist in tissue for decades.

The molecular pathway from asbestos exposure to malignancy involves chronic inflammation driven by frustrated phagocytosis (macrophages attempting and failing to engulf long asbestos fibers), generation of reactive oxygen species (ROS) causing oxidative DNA damage, inactivation of tumor suppressor genes (particularly BAP1, NF2, CDKN2A/p16), and interference with mitotic spindle function as fibers physically interact with dividing cells.

Genetic Susceptibility

Asbestos exposure explains the large majority of pleural mesothelioma, but it does not explain why only a small fraction of exposed people develop the disease. Inherited variation is part of the answer. In 2011, researchers identified germline BAP1 mutations in two families with a high incidence of mesothelioma, together with somatic BAP1 alterations in the resulting tumours — evidence of biallelic inactivation. The same work found germline BAP1 mutations in 2 of 26 sporadic mesotheliomas, in both cases in individuals previously diagnosed with uveal melanoma, defining a BAP1 cancer syndrome characterised by mesothelioma and uveal melanoma.

The significance is not only a matter of risk. Mesotheliomas arising in germline BAP1 carriers are significantly less aggressive than sporadic disease: some carriers have asymptomatic tumours that can be followed by close clinical observation and may survive many years without therapy, while others respond well to treatment. Identifying a carrier therefore changes management for that patient and allows screening of relatives. ASCO's 2025 guideline update, Recommendation 7.1, states that all patients with mesothelioma should be offered germline testing (evidence quality High; strength of recommendation Strong). The European BAP1-TPDS consensus is more restrictive, advising that testing "should not routinely be offered" in isolated mesothelioma while allowing it to be considered on age of onset and factors such as absence of asbestos exposure (95% consensus, Moderate /weak), and recording at 81% and rated Strong that "the prevalence of germline BAP1 pathogenic variants in individuals with isolated mesothelioma is low (less than 3%)".

Genetic predisposition and asbestos exposure are not competing explanations. The original description of the syndrome proposed that mesothelioma predominates upon asbestos exposure in carriers — inherited susceptibility lowers the threshold at which exposure produces disease rather than replacing exposure as the cause. Identifying a germline mutation in an individual patient does not by itself establish it as the cause of that patient's disease: on the syndrome's own proposed mechanism, asbestos exposure remains the operative trigger in carriers.

"There are evidences that suggest that few specific genetic mutations play a pivotal role in mesothelioma carcinogenesis and/or aggressiveness. Therefore the genetic factor should be considered when any other significant exposure to another causative agent has been carefully ruled out."
— Luciano Mutti, MD, PhD, in expert review of this page

Latency Period

The latency period between initial asbestos exposure and mesothelioma diagnosis is exceptionally long, typically 20 to 50 years with a median of approximately 40 to 45 years. This extended latency means that workers exposed to asbestos in the 1960s through 1980s — the peak era of industrial asbestos use — continue to be diagnosed today. The latency period does not vary significantly with cumulative exposure dose, though higher exposures may slightly shorten the time to diagnosis. The Italian National Mesothelioma Register (ReNaM), analysing 8,868 pleural mesothelioma cases, recorded a mean latency of 43.7 years among occupationally exposed workers.

Occupational and Environmental Exposure

The vast majority of pleural mesothelioma cases (80–90%) are attributable to occupational asbestos exposure. Workers in high-risk occupations include insulation workers (who face the highest risk at 46 times the expected mortality rate), boilermakers, shipyard workers, plumbers and pipefitters, construction workers, power plant workers, and steel mill workers.

Secondary (take-home) exposure also accounts for a meaningful percentage of cases, occurring when workers carried asbestos fibers home on their clothing, hair, and skin, exposing family members — particularly spouses who laundered contaminated work clothes. Environmental exposure from naturally occurring asbestos deposits or proximity to asbestos-processing facilities has also been documented.

What Compensation Is Available for Pleural Mesothelioma?

Patients diagnosed with pleural mesothelioma and their families may be eligible for significant financial compensation through multiple legal avenues. Given the established causal link between asbestos exposure and mesothelioma, the legal system provides several pathways to recovery, including personal injury and wrongful death litigation and claims against bankruptcy trusts established under Section 524(g) of the U.S. Bankruptcy Code.

Asbestos Trust Funds

More than 60 asbestos bankruptcy trusts hold $16.0-$21.8 billion (moving target) in remaining funds designated for asbestos disease victims, established under Section 524(g) of the U.S. Bankruptcy Code. These trusts pay claimants a "payment percentage" of a predetermined scheduled value for each disease category. Mesothelioma claimants receive the highest payment categories due to the severity of the disease. An experienced mesothelioma attorney can identify all applicable trusts based on a patient's specific exposure history and file claims simultaneously against multiple trusts. See Asbestos_Trust_Funds and Mesothelioma_Claim_Process for detailed filing guidance.

The table below shows estimated Expedited Review (ER) payouts for mesothelioma claims at major trusts. Each payment percentage is the rate stated in the issuing trust's own most recent payment-percentage notice; payout figures are the product of that rate and the trust's scheduled value, not separately published amounts:

Trust Name	Parent Company	Payment %	Meso ER Scheduled Value	Actual ER Payout
DII Industries (Halliburton)	Dresser Industries / Halliburton	60%	$60,718.95	~$36,431
W.R. Grace (WRG)	W.R. Grace & Co.	30.1%	$180,000	~$54,180
Pittsburgh Corning	Pittsburgh Corning Corp.	19%	$175,000	~$33,250
National Gypsum (NGC)	National Gypsum Co.	45%	Adjusted annually	Varies
Manville (Johns-Manville)	Johns-Manville Corp.	~5.1%	$350,000	~$17,850
USG Corporation	USG Corporation (U.S. Gypsum)	10%	$155,000	~$15,500
Armstrong World Industries	Armstrong World Industries	10.8%	$110,000	~$11,880
Owens Corning Sub-Account	Owens Corning Fiberglass	4.3%	$215,000	~$9,245
Celotex	Celotex Corp. / Carey Canada	7%	$130,000	~$9,100

Payment percentages reflect each trust's most recently published notice, the latest of which is dated June 30, 2026. Where a trust has noticed a reconsideration that was not yet re-determined when this table was compiled — Armstrong World Industries, noticed June 11, 2026 — the figure shown is the last percentage that trust published, and its reference says so. Payouts are calculated as Scheduled Value × Payment Percentage and are estimates, not separately published figures. Individual Review (IR) claims are valued differently and may yield substantially higher amounts; a trust's published average or maximum value is an IR figure and is not the Expedited Review scheduled value shown above. Payment percentages are periodically re-determined and have moved in both directions, so a claimant's actual recovery depends on the rate in effect when the claim is paid.

Most patients with documented asbestos exposure qualify for claims against multiple trusts simultaneously. An attorney experienced in asbestos litigation can typically identify 5–15 applicable trusts per case, with combined payouts ranging from $25,000 to $200,000+ through the Expedited Review process. Individual Review claims and case-value trusts may yield substantially more.

For detailed information about specific trusts, see Johns_Manville_Trust, Owens_Corning_Trust, Pittsburgh_Corning_Trust, WR_Grace_Trust, and USG_Trust.

Personal Injury Lawsuits

Patients diagnosed with mesothelioma may file personal injury lawsuits against the companies responsible for their asbestos exposure. Combined recoveries across all sources — trust claims, litigation and VA benefits together — typically fall in the $1.5 to $3 million range, and trial verdicts can reach substantially higher amounts. These are qualified process descriptions rather than guarantees or predicted outcomes. Key factors influencing settlement value include the extent of documented exposure, the number of identifiable defendants, the jurisdiction, and the severity of the patient's condition.

VA Benefits for Veterans

Military veterans represent a significant proportion of mesothelioma patients due to the extensive use of asbestos in naval vessels, military facilities, and equipment throughout the 20th century. Veterans diagnosed with mesothelioma may be eligible for VA disability compensation (rated at 100% for mesothelioma), Dependency and Indemnity Compensation (DIC) for surviving family members, Aid and Attendance benefits, and VA healthcare at specialized treatment facilities. Filing VA benefits claims does not affect eligibility for civil lawsuits or trust fund claims. The 100% rating derives from VA diagnostic code 6819, which assigns a 100 percent evaluation to malignant neoplasms of any specified part of the respiratory system. Under that code the 100 percent rating does not drop automatically when treatment stops — it stays in place after the veteran finishes treatment, and the rating is only reassessed at a mandatory VA examination six months after treatment is discontinued.

For more information, see Veterans_Benefits and Military_Exposure_Overview.

Wrongful Death Claims

When a mesothelioma patient passes away, surviving family members may file wrongful death lawsuits to recover compensation for medical expenses, lost income, funeral costs, and loss of companionship. Each state has its own statute of limitations for wrongful death claims, making timely legal consultation essential.

⚠ Important: Statutes of limitations vary by state and begin running from the date of diagnosis or death. Patients and families should consult with an experienced mesothelioma attorney promptly to preserve their legal rights.

What Are the Latest Research Advances?

Research into pleural mesothelioma treatment continues to advance rapidly, with several promising developments that may reshape the treatment landscape in coming years.

CheckMate 743 Long-Term Follow-Up

The most significant survival data update in 2026 is the 5-year follow-up of CheckMate 743, published in the Journal of Clinical Oncology. The overall 5-year survival rate was 14% with nivolumab + ipilimumab versus 6% with chemotherapy, confirming durable long-term benefit. Notably, 17% of responders in the immunotherapy arm maintained ongoing responses at 5 years, compared to 0% in the chemotherapy arm — demonstrating that immunotherapy can produce exceptional durability in a subset of patients. For non-epithelioid disease specifically, 5-year overall survival was 12% versus 1% (HR 0.48; 95% CI 0.33–0.68), against 14% versus 8% in epithelioid disease (HR 0.85; 95% CI 0.69–1.03). These data informed the NCCN Category 1 recommendation for non-epithelioid disease. An independent reanalysis has, however, reported differential censoring in this trial favouring the control arm in both the intention-to-treat and non-epithelioid populations, and found no significant survival difference between CheckMate 743 and the earlier MAPS regimen — see how these results should be read. See Mesothelioma_Immunotherapy for full immunotherapy coverage.

KEYNOTE-483 Updated Results

Updated 1-year follow-up data for the pembrolizumab + pemetrexed + platinum regimen (KEYNOTE-483/IND227), presented in December 2025, confirmed that the OS benefit is maintained over time (21% improvement vs. chemotherapy alone). The combination achieved median OS of 17.3 months versus 16.1 months (HR 0.79; p=0.0162), with 3-year OS rates of 25% versus 17% and ORR of 52% versus 29%. The benefit was particularly pronounced in non-epithelioid patients (median OS 12.3 vs. 8.2 months; HR 0.57), making this an alternative option for sarcomatoid and biphasic histologies.

Ongoing Phase III Trials

Two trials highlighted at the 2025 NCCN Annual Conference may further reshape first-line treatment:

DREAM3R Trial: This Phase III study is evaluating durvalumab (anti-PD-L1) plus chemotherapy versus chemotherapy alone specifically for epithelioid mesothelioma. If positive, DREAM3R would add a chemoimmunotherapy option for epithelioid disease alongside the four Category 1 preferred first-line options NCCN already lists for that histology, including ipilimumab + nivolumab. The design is not without precedent-based objection: a reconstruction of individual patient data across four frontline trials found that durvalumab added to pemetrexed and cisplatin worsened overall survival relative to chemotherapy controls, the only one of four novel regimens examined to do so.

eVOLVE-meso Trial: This study is investigating volrustomig (a bispecific anti-PD-1/CTLA-4 antibody) combined with chemotherapy, representing a next-generation approach to dual checkpoint blockade using a single molecule. Results from both trials are expected to inform future NCCN guideline updates.

Perioperative Immunotherapy

In a phase II trial led from Johns Hopkins, presented at WCLC 2025 and published concurrently in Nature Medicine, patients with resectable disease received neoadjuvant nivolumab (Arm A, n=16) or nivolumab + ipilimumab (Arm B, n=14). In the nivolumab-plus-ipilimumab arm, 85.7% (12/14) proceeded to surgery, with median PFS of 19.8 months and median OS of 28.6 months; the nivolumab-alone arm reported 81.3% (13/16), 9.6 months and 19.3 months. The arms enrolled sequentially rather than randomised, so they are not a controlled comparison. Circulating tumor DNA (ctDNA) tracked surgical outcome: persistent ctDNA during neoadjuvant therapy identified patients who did not achieve complete resection because of disease progression (p=0.00013). The 2025 ASCO guidelines conditionally recommend offering neoadjuvant immunotherapy to surgical candidates. The European guidelines are explicit about where such patients belong: those considered candidates for a multimodal approach including radical surgery should be treated as part of clinical trials at mesothelioma-dedicated centres.

"If the patient is fit with early disease, the best option is surgery aimed at macroscopic complete resection and adjuvant chemotherapy. As far as ICI-induction, the very same comments are even more valid in this setting."
— Luciano Mutti, MD, PhD, in expert review of this page

Biomarker-Guided Treatment

No biomarker is currently validated to select patients for immunotherapy in pleural mesothelioma. Both the NCCN and the 2025 ASCO guideline specify that PD-L1 expression, tumour mutational burden and MSI status should not be used to guide treatment selection. Histological subtype — epithelioid versus non-epithelioid — remains the primary decision driver.

BAP1 and CDKN2A (p16) do have an established role, but it is a diagnostic one: the European guidelines recommend them to separate atypical mesothelial proliferation from malignant mesothelioma in the roughly 10% of cases where conventional staining is insufficient. A diagnostic marker is not a predictive one, and neither gene has been validated as a predictor of immunotherapy benefit. ASCO's 2025 guideline update, Recommendation 7.1, states that all patients with mesothelioma should be offered germline testing (evidence quality High; strength of recommendation Strong) — that is a matter of inherited cancer predisposition and family screening, not drug selection.

Liquid Biopsy and Early Detection

Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) has shown promise as a non-invasive diagnostic tool, achieving 91% accuracy in distinguishing mesothelioma patients from asbestos-exposed controls in a proof-of-concept study.

How much tumour DNA actually reaches the bloodstream is the limiting factor, and it is not much. A feasibility study performing whole-exome sequencing on 14 tumour biopsies and then tracking 20 patient-specific somatic mutations by droplet digital PCR found the mutations detectable in 94% of pleural fluid samples but in plasma at a median mutant fraction of only 0.29%, against 21.95% in the matched solid biopsies — a highly significant drop. Pleural fluid, by contrast, carried mutant fractions close to those of solid tissue (median 12.75%). Liquid biopsy in mesothelioma is therefore feasible, but pleural fluid is the more reliable compartment, and blood-based testing is working with a very small signal.

Targeted Therapies

ADI-PEG20 (Pegargiminase): An arginine-depleting therapy for tumors that have lost argininosuccinate synthetase 1 (ASS1), a deficiency more common in non-epithelioid mesothelioma. In the phase I TRAP dose-expansion cohort, 32 chemotherapy-naive patients with ASS1-deficient mesothelioma (11 epithelioid, 10 biphasic, 11 sarcomatoid) received pegargiminase with pemetrexed and cisplatin; disease control was achieved in 93.5% (29/31 evaluable) and partial response in 35.5%, with median PFS of 5.6 months and median OS of 10.1 months. Enrollment was gated on ASS1 deficiency rather than histology. The randomized ATOMIC-Meso trial subsequently tested the combination in 249 patients with non-epithelioid mesothelioma, reporting median overall survival of 9.3 months versus 7.7 months with placebo (HR 0.71). The ASCO 2025 guidelines conditionally recommend ADI-PEG20 + chemotherapy for non-epithelioid patients who cannot receive immunotherapy. A Biologics License Application is under review with the FDA.

VT3989 (Hippo Pathway Inhibitor): An oral TEAD palmitoylation inhibitor that disrupts YAP transcriptional activity. Its first-in-human phase 1/2 trial in refractory solid tumours has now reported: 172 patients, 135 of them with mesothelioma, with an objective response rate of 26% among 47 mesothelioma patients treated at clinically optimised doses, rising to 32% (disease control rate 86%, median PFS 10 months) in a 22-patient subset when urine albumin:creatinine thresholds were also applied. Toxicity was mostly grade 1–2, with reversible proteinuria the characteristic effect. The FDA has granted orphan drug and fast-track designation for mesothelioma.

Note that the trial enrolled on refractory solid tumour status rather than on NF2 status. NF2 loss is not an established predictive biomarker for this pathway. Preclinical work comparing YAP/TAZ-TEAD inhibitors has identified genetic compensation within the Hippo transcriptional module, with direct implications for therapeutic targeting, and a 2026 biomarker review places NF2/YAP/TEAD among targets for early-phase trials rather than among markers ready to guide treatment.

"This is one of the few science-based trials. Just a caveat: as for their own admission, NF2 and Merlin are not that solid biomarkers. In general terms much depends on the tumour microenvironment."
— Luciano Mutti, MD, PhD, in expert review of this page

CDK4/6 Inhibitors: Under investigation given that CDKN2A deletion occurs in approximately 45% of mesotheliomas, potentially enabling a precision medicine approach based on tumor molecular profiling. Early results have drawn a published methodological objection. The MiST2 trial — single-arm, open-label, phase 2, 26 patients with p16^ink4A-deficient mesothelioma progressing after platinum-based chemotherapy — reported disease control at 12 weeks in 14 of 26 patients (54%; 95% CI 36–71), meeting a pre-specified null that could be rejected at 11 of 26, or 42%. A critique in Lancet Oncology argued that disease control rate does not mirror overall survival in mesothelioma, that a null set at 42% is very modest, and that the results were compared against CONFIRM and CheckMate 743 without acknowledging the control-arm caveats attached to those trials. The trial investigators published a reply. MiST2 was single-arm, so it carries no internal comparator of its own; its authors concluded that the result warrants further investigation in a randomised study.

Real-World vs. Clinical Trial Outcomes

Real-world outcomes diverge from trial results in both directions, and which direction depends on the treatment.

For chemotherapy the real-world figures can look better than the trial figures. In one cohort, epithelioid patients receiving cisplatin plus pemetrexed achieved median OS of 30.7 months against the 12–16 months seen in clinical trials, likely reflecting patient selection at specialised centres; non-epithelioid patients in the same cohort achieved 17.2 months.

For combination immunotherapy the gap runs the other way. RIOMeso, a retrospective study of 119 Australian patients treated with ipilimumab and nivolumab across 11 centres, reported median overall survival of 14.5 months — against 18.1 months in CheckMate 743 — with 24% experiencing grade 3 or worse adverse events and three treatment-related deaths. The survival difference between epithelioid and non-epithelioid patients did not reach statistical significance in that cohort (19.1 versus 13.0 months; p=0.064). Its authors concluded that combination immunotherapy in routine practice has poorer survival outcomes and appears more toxic than the trial data suggest.

A second real-world cohort points the same way. Among 109 patients treated at twelve Swiss centres between November 2017 and March 2023, median overall survival from the start of ipilimumab plus nivolumab was 12.6 months in the first-line setting and 6.9 months in the second line or later, with objective response rates of 21% and 15% respectively. Performance status separated outcomes sharply: median OS was 2.4 months for patients with ECOG 2 or worse against 11.9 months for ECOG 0–1 (p<0.001). Treatment-related adverse events of any grade occurred in 62% of patients, and 22% discontinued because of one. The authors concluded that survival outcomes were inferior to those reported in CheckMate 743 and MAPS2 while safety outcomes were similar.

A separate Australian audit of 90 patients found 12-month overall survival of 72% with immunotherapy against 64% with chemotherapy — not a statistically significant difference (HR 1.28; 95% CI 0.65–2.5; p=0.5). In that cohort 37% of patients received best supportive care as their first-line management, and of those who were treated, only 40% went on to any second-line therapy.

A published commentary draws the comparison these cohorts invite. Professor Luciano Mutti, who serves as medical reviewer for this page, is an author of the commentary described in this paragraph. Reading the Australian results alongside a Dutch series of 184 patients (median OS 14.1 months), Gray, Meirson and Mutti observe that real-world median survival on dual immunotherapy sits close to the chemotherapy arm of CheckMate 743 (14.1 months) rather than to its immunotherapy arm (18.1 months) — a comparison they note carries the inherent limitations of cross-study comparison. The commentary concludes that current data are "not sound enough to currently warrant its use for all-comers," against roughly a twofold increase in drug discontinuation and up to three times more serious adverse events or treatment-related deaths. It also argues the burden falls unevenly — that the epithelioid subgroup "experiences severe toxicity with no apparent benefit, whereas the nonepithelioid subtype has the same toxicities with a strong suggestion for benefit."

Taken together these data underscore the importance of treatment at experienced mesothelioma treatment centers with multidisciplinary expertise — and the value of asking what a regimen has achieved outside a trial population, not only within one.

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Frequently Asked Questions

What is the survival rate for pleural mesothelioma?

The overall 5-year relative survival rate for pleural mesothelioma is approximately 12% according to SEER data spanning 2000–2020. However, survival varies considerably by stage and subtype. Stage I patients achieve 18–20% five-year survival, while Stage IV patients reach only 7–8%. Epithelioid histology carries the most favorable prognosis at 12–27 months median survival, compared to 4–8 months for sarcomatoid disease. Patients treated with multimodal therapy at specialized centers tend to outlive those receiving standard care alone.

Is pleural mesothelioma curable?

Pleural mesothelioma is not considered curable in most cases, though long-term survival is achievable for a subset of patients. Selected individuals with early-stage, epithelioid disease who undergo multimodal treatment — combining surgery, chemotherapy, and immunotherapy — have achieved 5-year survival rates exceeding 20%. The durability of immunotherapy responses offers additional hope, with 28% of responders to nivolumab plus ipilimumab maintaining their response at 3 years.

What is the best treatment for pleural mesothelioma?

The optimal treatment depends on histological subtype, disease stage, and overall patient health. For non-epithelioid (sarcomatoid and biphasic) mesothelioma, nivolumab plus ipilimumab is recommended as first-line therapy based on CheckMate 743 results. For epithelioid disease, cisplatin plus pemetrexed or pembrolizumab plus chemotherapy are standard options. Surgery is now reserved for early-stage, node-negative, epithelioid disease at high-volume centers. Treatment at a specialized mesothelioma center with a multidisciplinary team offers the best outcomes.

How is pleural mesothelioma different from lung cancer?

Pleural mesothelioma and lung cancer are distinct diseases despite both affecting the chest cavity. Mesothelioma originates in the pleural lining surrounding the lungs and grows as a diffuse, sheet-like tumor, whereas lung cancer forms a discrete mass within the lung tissue itself. Mesothelioma is caused almost exclusively by asbestos exposure with a 20–50 year latency period, while lung cancer has multiple risk factors including smoking. The two cancers require different diagnostic markers, staging systems, and treatment approaches.

What causes pleural mesothelioma?

Asbestos exposure is the established cause in 80–90% of pleural mesothelioma cases. Inhaled asbestos fibers migrate to the pleural space and trigger decades-long chronic inflammation, oxidative DNA damage, and inactivation of tumor suppressor genes including BAP1, NF2, and CDKN2A. The latency period between exposure and diagnosis spans 20 to 50 years with a median of 40–45 years. Most cases arise from occupational exposure in trades such as insulation work, shipbuilding, and construction, though secondary household exposure also contributes. A small minority of patients carry an inherited BAP1 mutation that predisposes them to mesothelioma; this lowers the threshold at which asbestos causes disease rather than acting as an alternative cause, and ASCO's 2025 guideline update, Recommendation 7.1, states that all patients with mesothelioma should be offered germline testing (evidence quality High; strength of recommendation Strong). See genetic susceptibility.

What are the symptoms of pleural mesothelioma?

Early symptoms are often nonspecific and include persistent dry cough, progressive shortness of breath, chest pain, and unexplained fatigue. Pleural effusion — fluid accumulation between the pleural layers — is the most common presenting finding, absent at diagnosis in only 10.79% of a 3,384-patient SEER cohort. Advanced disease may produce significant weight loss, night sweats, difficulty swallowing, and palpable chest wall masses. Because symptoms mimic common respiratory conditions, diagnostic delays of 3 to 6 months are typical.

Can pleural mesothelioma be caught early?

Early detection remains challenging because symptoms are nonspecific and overlap with common respiratory conditions. There is currently no widely adopted screening program for mesothelioma, though emerging biomarker approaches — including multi-biomarker panels achieving sensitivities exceeding 90% and liquid biopsy techniques with 91% diagnostic accuracy — show promise for earlier detection in high-risk populations. Anyone with a history of asbestos exposure who develops persistent respiratory symptoms should inform their physician of their exposure history to prompt appropriate diagnostic workup.

What compensation is available for pleural mesothelioma?

Multiple compensation pathways exist for pleural mesothelioma patients and their families. More than 60 asbestos bankruptcy trusts hold $16.0-$21.8 billion (moving target) in remaining funds. Combined recoveries across trust claims, litigation and VA benefits typically fall in the $1.5 to $3 million range. Figures are qualified process descriptions, not guarantees or predicted outcomes.

Military veterans exposed to asbestos during service may qualify for VA disability compensation, and mesothelioma is rated at 100% under VA diagnostic code 6819. Additional benefits including Aid and Attendance and Dependency and Indemnity Compensation for surviving family members may also apply. Veterans may pursue VA benefits alongside civil litigation and trust-fund claims.

Quick Statistics

• U.S. mesothelioma incidence has declined 40% over two decades, from 1.08 per 100,000 in 2003 to 0.65 per 100,000 in 2022, reflecting the phased reduction in asbestos use beginning in the 1970s
• Between 2003 and 2022, a cumulative total of 63,620 mesothelioma cases were reported in the United States, with approximately 2,236 mesothelioma deaths recorded in 2022 alone
• Among patients aged 71–80, the diagnosis rate is highest at 33.5% of all cases, while 23.1% of patients are diagnosed over age 80
• The United Kingdom, Australia, Italy, and the Netherlands report among the highest per-capita mesothelioma rates globally, correlating with historical patterns of industrial asbestos consumption; the Global Burden of Disease 2019 systematic analysis documented continued worldwide mesothelioma mortality with national-level disparities tracking the timing and rigor of historical asbestos regulation
• Liquid biopsy using cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) achieved 91% accuracy distinguishing mesothelioma from asbestos-exposed controls in proof-of-concept testing; separately, tumour DNA reaches plasma only weakly — a median mutant fraction of 0.29% against 21.95% in matched solid biopsy — making pleural fluid the more reliable compartment
• ADI-PEG20 (pegargiminase) with pemetrexed/cisplatin achieved 93.5% disease control (29/31 evaluable) in the TRAP phase I expansion cohort of ASS1-deficient patients — a cohort of 11 epithelioid, 10 biphasic and 11 sarcomatoid, selected on ASS1 loss rather than histology; median overall survival was 10.1 months
• Tumor Treating Fields (TTFields/Optune Lua) reported median OS of 18.2 months in the 80-patient single-arm STELLAR trial; with no control group and no randomised trial since, the 2025 ASCO guideline finds insufficient evidence to recommend for or against it
• HITHOC (heated intraoperative chemotherapy) was associated with improved OS of 20.5 vs. 16.8 months (HR 0.80) in a National Cancer Database analysis of 3,232 patients
• Approximately 20% of biopsies initially classified as epithelioid reveal biphasic features in full resection specimens, suggesting the biphasic subtype may be underdiagnosed
• CDKN2A deletion occurs in approximately 45% of mesotheliomas, making CDK4/6 inhibitors an active area of clinical investigation; the MiST2 single-arm trial of abemaciclib reported disease control at 12 weeks in 14 of 26 patients (54%), a result whose endpoint and comparators have been challenged in print

Related Pages

• Understanding_Your_Diagnosis — Comprehensive diagnosis guide
• Mesothelioma_Treatment_Centers — Specialized care facilities
• Clinical_Trials — Current research studies
• Asbestos_Trust_Funds — Compensation overview
• Veterans_Benefits — VA benefits for veterans
• Emergency_Action_Checklist — First steps after diagnosis
• Occupational_Exposure_Index — High-risk occupations
• Medical_Terms_Glossary — Key medical terminology

External Links

• Danziger & De Llano — Mesothelioma attorneys; can connect families with specialized pleural mesothelioma treatment centers.
• Mesothelioma Lawyer Center — Treatment options, clinical trials, and legal rights resources.
• Mesothelioma.net — Comprehensive pleural mesothelioma treatment and prognosis information.

Medically reviewed by Dr. Luciano Mutti, MD, PhD — Professor of Oncology, UniCamillus, Rome · Medical Oncology
Last reviewed: 2026-08-27 · Medical review covers clinical accuracy only and is not an endorsement of any legal service. See Editorial Standards for our editorial process.